| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.32 | 5e-09 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.33 | 5e-07 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.26 | 6e-07 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.3 | 2e-06 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.18 | 4e-06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.25 | 9e-06 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.17 | 2e-05 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.0002 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0005 |